Tag: ADA 2026
Orforglipron Shows Clinically Significant HbA1c Reductions in Type 2 Diabetes
Two phase III randomised controlled trials presented at the American Diabetes Association conference in June 2026 demonstrate that orforglipron, a…
Eli Lilly Reports Safety Data for Next-Generation Obesity Drug Retatrutide
Eli Lilly presented new safety data for retatrutide, its triple-hormone obesity drug, at the 2026 American Diabetes Association meeting. The…
Submit Your Paper to GMJ
No APC until January 2027.